Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:DSENYSE:RDY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDSEDuff & Phelps Select MLP and Midstream Energy Fund$9.49$9.31$3.40▼$10.00N/AN/A26,659 shs73,162 shsRDYDr. Reddy's Laboratories$15.23-3.1%$14.28$12.26▼$16.89$13.19B0.331.51 million shs1.60 million shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDSEDuff & Phelps Select MLP and Midstream Energy Fund0.00%0.00%0.00%0.00%0.00%RDYDr. Reddy's Laboratories-0.68%+0.36%+8.70%+17.49%+9.19%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDSEDuff & Phelps Select MLP and Midstream Energy FundN/AN/AN/AN/AN/AN/AN/AN/ARDYDr. Reddy's Laboratories2.7791 of 5 stars2.53.01.70.03.30.01.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDSEDuff & Phelps Select MLP and Midstream Energy Fund 0.00N/AN/AN/ARDYDr. Reddy's Laboratories 3.00Buy$16.9511.31% UpsideCurrent Analyst Ratings BreakdownLatest DUB, DSE, RDY, and TSK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/5/2025RDYDr. Reddy's LaboratoriesHsbc Global ResSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy6/5/2025RDYDr. Reddy's LaboratoriesHSBCSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$14.44 ➝ $16.90(Data available from 6/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDSEDuff & Phelps Select MLP and Midstream Energy FundN/AN/AN/AN/AN/AN/ARDYDr. Reddy's Laboratories$3.81B3.34$1.00 per share15.30$4.73 per share3.22Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDSEDuff & Phelps Select MLP and Midstream Energy FundN/AN/A0.00∞N/AN/AN/AN/AN/ARDYDr. Reddy's Laboratories$663M$0.6623.0718.576.4617.38%17.98%12.24%7/25/2025 (Estimated)Latest DUB, DSE, RDY, and TSK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q4 24/25RDYDr. Reddy's Laboratories$0.20$0.22+$0.02$0.22$83.70 billion$996.17 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDSEDuff & Phelps Select MLP and Midstream Energy Fund$0.606.32%N/AN/AN/ARDYDr. Reddy's Laboratories$0.080.53%N/A12.12%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDSEDuff & Phelps Select MLP and Midstream Energy FundN/AN/AN/ARDYDr. Reddy's Laboratories0.021.921.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDSEDuff & Phelps Select MLP and Midstream Energy FundN/ARDYDr. Reddy's Laboratories3.85%Insider OwnershipCompanyInsider OwnershipDSEDuff & Phelps Select MLP and Midstream Energy FundN/ARDYDr. Reddy's Laboratories2.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDSEDuff & Phelps Select MLP and Midstream Energy FundN/AN/AN/ANot OptionableRDYDr. Reddy's Laboratories27,811834.77 million818.08 millionOptionableDUB, DSE, RDY, and TSK HeadlinesRecent News About These CompaniesGAMMA Investing LLC Purchases 66,049 Shares of Dr. Reddy's Laboratories Limited (NYSE:RDY)June 17 at 3:14 AM | marketbeat.comRhumbline Advisers Sells 86,773 Shares of Dr. Reddy's Laboratories Limited (NYSE:RDY)June 14 at 3:20 AM | marketbeat.comStanley Laman Group Ltd. Makes New $1.85 Million Investment in Dr. Reddy's Laboratories Limited (NYSE:RDY)June 13, 2025 | marketbeat.comDr. Reddy's Laboratories rallies Tuesday, outperforms competitorsJune 10, 2025 | marketwatch.comDr. Reddy's Laboratories Reaches Analyst Target PriceJune 8, 2025 | nasdaq.comDr. Reddy's Laboratories (NYSE:RDY) Upgraded at Hsbc Global ResJune 7, 2025 | americanbankingnews.comDr. Reddy's Laboratories (NYSE:RDY) Upgraded to "Buy" at HSBCJune 7, 2025 | americanbankingnews.comHSBC Upgrades Dr. Reddy's Laboratories Limited - Depositary Receipt () (RDY)June 6, 2025 | msn.comDr. Reddy's Laboratories (NYSE:RDY) Upgraded by Hsbc Global Res to "Strong-Buy" RatingJune 6, 2025 | marketbeat.comHSBC Upgrades Dr. Reddy’s Laboratories Limited (RDY) to Buy from HoldJune 5, 2025 | msn.comDr. Reddy's Laboratories rallies Thursday, outperforms competitorsJune 5, 2025 | marketwatch.comHSBC upgrades Dr Reddy’s on weight loss drug semaglutide-driven earnings reboundJune 5, 2025 | in.investing.comDr. Reddy’s stock rises on biosimilar collaboration with AlvotechJune 5, 2025 | investing.comDr. Reddy's Laboratories (NYSE:RDY) Shares Gap Up - Time to Buy?June 5, 2025 | marketbeat.comRDY & ALVO Ink Collaboration Deal for Merck's Keytruda BiosimilarJune 5, 2025 | zacks.comDr. Reddy's Laboratories (NYSE:RDY) Raised to "Buy" at HSBCJune 5, 2025 | marketbeat.comAlvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)June 5, 2025 | businesswire.comAlvotech and Dr. Reddy’s partner to co-develop biosimilar candidate for Keytruda (pembrolizumab)June 5, 2025 | msn.comAlvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)June 5, 2025 | finance.yahoo.comDr. Reddy’s Labs ADR Stock Price HistoryJune 4, 2025 | investing.comDr. Reddy's Laboratories rises Wednesday, underperforms marketJune 4, 2025 | marketwatch.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDUB, DSE, RDY, and TSK Company DescriptionsDuff & Phelps Select MLP and Midstream Energy Fund NYSE:DSEDuff & Phelps Select Energy MLP Fund Inc. is a closed-ended equity mutual fund launched by Virtus Investment Partners, Inc. The fund is co-managed by Duff & Phelps Investment Management Co. and Virtus Alternative Investment Advisers, Inc. It invests in the public equity markets of the United States. The fund seeks to invest in stocks of companies operating in the energy sector, with an emphasis on companies involved in the business of exploring, developing, producing, gathering, transporting, processing, storing, refining, distributing, mining, or marketing natural gas, natural gas liquids (including propane), crude oil, refined petroleum products or coal. It primarily invests in equity securities of midstream MLPs and stocks of companies across all market capitalizations. The fund employs both fundamental and quantitative analysis with a bottom-up stock picking approach, focusing on such factors as management philosophy and track record, competitive advantages via barriers to entry, long-term customer relationships and geographic footprint, regulatory landscape via permitting and export laws, quality of asset drop-down inventory including right of first offer, and assessment of fee-based contract structure including minimum volume commitments, inflation escalators, and take-or-pay provisions to create its portfolio. Duff & Phelps Select Energy MLP Fund Inc. was formed on March 28, 2014 and is domiciled in the United States.Dr. Reddy's Laboratories NYSE:RDY$15.23 -0.49 (-3.13%) Closing price 03:59 PM EasternExtended Trading$15.15 -0.08 (-0.51%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analyst Downgrades Joby, But Overlooks Major Regulatory Wins Applied Digital: Now the High-Stakes Race to Build Begins Zscaler Upgraded: Wall Street Forecasts 26% More Upside U.S. Steel Stock Burns the Bears With Surprise Upside Move Is CrowdStrike Stock Set to Break Out or Cool Off? New Catalysts to Drive NVIDIA’s Stock Price Even Higher Palantir Defies Bears, Leads S&P 500 in 2025 The Bottom Is in for Powerfleet: An Intelligent Time to Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
